Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Recruiting Industry Experts is Key to Success for Cannabis Companies

Published

on

Reading Time: 6 minutes

 

The cannabis industry is seen by professionals as one of the most exciting fields to participate in, with many companies attracting some of the brightest industry experts to join them. Agraflora Organics International (CSE:AGRA) (OTC:PUFXF), National Access Cannabis Corp (CSE:META) (OTC:NACNF), CBD Unlimited, Inc (CSE:EDXC) (OTC:EDXC), FSD Pharma Inc (CSE:HUGE) (OTC:FSDDF) and Chemistree Technology Inc(OTC:CHMJF) (CSE:CHM) have all been working hard to sign on cannabis experts in an effort to gain a competitive advantage over their competition.

As the relatively young cannabis industry continues to mature, one of the best predictors of whether a company will survive in the years to come is the strength of its management team. With becoming increasingly fierce, companies led by management teams with plenty of experience – drawn from both within and outside the cannabis industry – have historically had the best likelihood of success. While every company strives to enlist top cannabis industry veterans – the truth of the matter is, these individuals are a rare find. The addition of experts to any cannabis company not only is a big deal in terms of publicity, but also a strong indicator of future success.

The Importance of Experienced Management Teams

The sheer growth potential of the cannabis industry has attracted some of the best executive talents across the world. According to Grand View Research, marijuana is predicted to become a $146.4 billion market globally by 2025, representing a 34.6 percent increase every year. With such growth opportunities available, it’s not surprising why many executives from Fortune 500 companies chose to leave their safe and conventional career paths to take a risk in the cannabis sector.

Recent Expert Partnerships

Cannabis companies are bringing in experts from diverse backgrounds. Depending on the type of cannabis company, the list of experts includes professionals ranging from cannabis market veterans to retail and healthcare professionals, and even law enforcement. The board of Agraflora Organics International Inc (CSE:AGRA) (OTCMKTS:PUFXF) boasts twolongtime Toronto Police officers on their management team. While, FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) is headed by physician turned entrepreneur, Dr. Dr Raza Bokhari, Executive Co-Chairman & Interim CEO.

As such, it’s not surprising that cannabis companies go out of their way to partner with high profile figures. Last month, Aurora Cannabis Inc announced it was partnering with billionaire Nelson Peltz. The relationship would help the cannabis giant better position itself for potential retail partnerships.

A much smaller company, Chemistree Technology Inc (OTCQB:CHMJF) (CSE:CHM), recently made news as well when it signed on legendary cannabis industry veteran Nicholas J. Zitelli – known within the industry by his pen name “Nico Escondido”. As one of the most knowledgeable experts in the cannabis space, Nico Escondido has written hundreds of articles about the cannabis industry and best practices. He also founded the Cannabis Genetics Institute (CGI) in AmsterdamHolland, helping create custom cannabis strains to treat various medical conditions. Besides all of this, Nico Escondido is best known for being a principal at the High Times brand.

With a monthly magazine in publication since 1974, High Times is one of the best-known groups promoting and developing the cannabis culture. Publishing numerous books and documentaries, High Times also hosts the most prestigious marijuana-related competition in the world. The “Cannabis Cup” brings together industry experts, cannabis enthusiasts, and marijuana companies together across the world and holds contests in various product categories.

“I am very excited to join the Chemistree team” said Nico Zitelli in a press release. “Having known and worked with many of the team members in the past, I am confident we will be able build significant value in the Company and help define the future of the cannabis industry.”

For a company like Chemistree Technology Inc (CHMJF) (CHM), getting Zitelli on board is a big deal. As an early investor in the international cannabis sector that’s expanding their vertically integrated operations, the addition of Nico Zitelli to Chemistree Technology Inc (CHMJF) (CHM) will give the company the industry clout it needs to stand out in the market.

“As Chemistree continues its focus on building one of the world’s leading cannabis companies, it is critical to have an experienced board to put us in the best possible position to achieve success.  These are exciting times for Chemistree and Nico represents another outstanding addition to our board of directors on our path of rapid growth,” added Chemistree Technology Inc (CHMJF) (CHM) President Karl Kottmeier. “The High Times Cannabis Cup is the most prestigious and extensive cannabis-related competition in the world and having his broad knowledge/specialized expertise, impressive network and reputation will be invaluable assets to the Company’s strategic direction.”

It’s common for massive, multi-billion-dollar cannabis companies to boast impressive hires within the industry. Chemistree Technology Inc (CHMJF) (CHM), on the other hand, is a company with less than $20 million in market capitalization. The fact that this small cannabis company has signed on one of the top industry experts in cannabis is a major accomplishment for the firm. In comparison, few other companies of a similar size can expect such a major name to come on board – something that will propel Chemistree Technology Inc (OTCQB:CHMJF) (CSE:CHM) to a class well above its peers.

Further Cannabis Developments

Back in late March, Agraflora Organics International Inc (CSE:AGRA) (OTCPK:PUFXF) announced they had fully invested a $40 million equity participation agreement with Delta Organic Cannabis Corp. The agreement would see Agra own a 50 percent stake in the second largest cannabis greenhouse in Canada.

In a recent press release, National Access Cannabis Corp (CSE:META) (OTCPK:NACNF)  announced their financial figures for their operations since federal legalization. The company achieved over $20 million in retail sales since October 17, 2018. National Access Cannabis has 23 stores across Alberta and Manitoba and is the largest private cannabis retailer in the country. The company is headed by a team with years of experience in retail and healthcare.

Todd A. Davis, Co-Founder and CEO of CBD Unlimited, Inc (CSE:EDXC) (OTCPK:EDXC), formerly known as Endexx Corporation,  brings to the team years of experience in investment banking and entrepreneurship. The company has recently employed a private sales group to help expand the company’s product reach both in Canada as well as internationally. Initially launching as a 25-person sales team, CBD Unlimited is expected to grow this salesforce to up to 500 in the next two years.

Another cannabis company that made a major management team announcement was FSD Pharma Inc (CSE:HUGE) (OTCQB:FSDDF). In a recent press release, the company announced that Dr. Charles Pollack would be joining FSD as the Chairman of their Scientific Board. He brings a long history of clinical research in the areas of pain treatment, thrombosis, and reversing anticoagulation.

For a free research report on Chemistree (CSE:CHM) (OTC:CHMJF), visit potstocknews.com

Disclaimer: Potstocknews.com (PSN) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with PSN or any company mentioned herein. The commentary, views and opinions expressed in this release by PSN are solely those of PSN and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable PSN and FNM for any investment decisions by their readers or subscribers. PSN and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (PSN), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (PSN) has not independently verified or otherwise investigated all such information. None of the Author, PSN, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty five hundred dollars by PSN, a non-affiliated third party to distribute this release on behalf of Chemistree Technology Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PSN and FNM undertake no obligation to update such statements.

 

SOURCE Potstocknews.com

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

on

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

on

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

on

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending